论文部分内容阅读
目的:观察艾迪注射液联合GP化疗治疗晚期非小细胞肺癌临床疗效。方法:2008年1月—2010年12月收治晚期非小细胞肺癌101例,随机分为艾迪注射液联合GP的化疗组(治疗组)49例,单独GP化疗组(对照组)52例,入组患者至少接受2个周期以上的化疗,观察两组近期疗效、不良反应、生活质量和生存期。结果:其中100位患者随访至死亡或化疗后2年(对照组失访1人),治疗组和对照组总有效率分别为12例(24.5%)和16例(30.8%),中位生存期为15.0个月和15.1个月,1年生存率59.2%和56.8%,两年生存率分别为34.7%和17.6%。两组除中性粒细胞减少存在显著性差异,其他血小板减少、血红蛋白减少、胃肠道反应、肝肾功能损害、皮疹等不良反应发生率的没有显著性差异。结论:艾迪注射液联合GP化疗治疗晚期非小细胞肺癌没有提高患者的近期疗效,但有提高远期疗效和患者的生活质量的趋势,能减少化疗期间中性粒细胞减少的发生率和严重程度。
Objective: To observe the clinical effect of Aidi injection combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: From January 2008 to December 2010, 101 patients with advanced non-small cell lung cancer were randomly divided into Aidi injection combined with GP chemotherapy group (treatment group) 49 cases, GP alone chemotherapy group (control group) 52 cases, Patients in the study group received at least 2 cycles of chemotherapy, the two groups were observed short-term efficacy, adverse reactions, quality of life and survival. Results: 100 patients were followed up to death or 2 years after chemotherapy (control group lost one person). The total effective rate in treatment group and control group were 12 cases (24.5%) and 16 cases (30.8%), respectively. The median survival time The duration was 15.0 months and 15.1 months. The 1-year survival rates were 59.2% and 56.8% respectively. The two-year survival rates were 34.7% and 17.6% respectively. Neutropenia in both groups there was a significant difference, other thrombocytopenia, hemoglobin decreased, gastrointestinal reactions, liver and kidney dysfunction, rash and other adverse reactions no significant difference in the incidence. Conclusion: Aidi injection combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer does not improve the short-term efficacy of the patients. However, there is a tendency to improve long-term efficacy and quality of life of the patients and reduce the incidence and severity of neutropenia during chemotherapy degree.